Roswell Park Cancer Institute
Roswell Park Cancer Institute (RPCI) is a freestanding comprehensive cancer center and the nation’s first cancer research, treatment and education center – established by Dr. Roswell Park in 1898. Dr. Park’s revolutionary model of a multidisciplinary approach to cancer with scientists and clinicians working in concert and in consult has become the standard by which all modern-day comprehensive cancer centers are measured.
RPCI is the only Comprehensive Cancer Center in Western and Upstate New York –as designated by the National Cancer Institute. Since 1971, Roswell Park has held this prestigious designation, meaning the Institute’s combined research, treatment, and educational programs have weathered extensive peer review, met rigorous national standards, and made fundamental contributions to reducing the cancer burden.
In addition, the Institute is a member of the National Comprehensive Cancer Network (NCCN), an alliance of the nation’s leading cancer centers. The NCCN brings together the best minds in science to engineer continuous quality improvements in cancer care; improves the effectiveness of cancer care delivery through the ongoing collection and analysis of outcome data on a national basis; enhances communications and collaboration among member institutions; offers access to the latest, most promising clinical trials; and provides best practice guidelines and measurement tools. Many RPCI faculty serve on the NCCN panels that create the Clinical Practice Guidelines in Oncology the Internationally recognized standards for clinical policy in oncology, and the most comprehensive, most frequently updated clinical practice guidelines available in any area of medicine.
Roswell Park is dedicated to providing the highest quality total care to patients; to conducting research into the causes, treatment and prevention of cancer; and to educating the public and the next generation of those who study and treat cancer. Groundbreaking research by RPCI scientists has led to greater understanding of the nature of cancer and to major advances in cancer diagnosis and treatment that are now in use worldwide. RPCI instituted the nation’s first chemotherapy program, pioneered studies on the relationship between smoking and lung cancer and developed photodynamic therapy (PDT) and the prostate-specific antigen (PSA) blood test. RPCI’s comprehensive cancer genetics program, now under development at RPCI, will rival the world’s leading programs in that field. The Institute also made significant contributions to the landmark human genome project. RPCI’s Center for Pharmacology and Therapeutics is one of the few centers in the nation capable of all phases of drug development, from the conceptual stage through manufacturing and testing.
Over the last decade, RPCI has undergone major growth, helping to revitalize the region’s economy by adding new jobs, initiating one of the nation’s first hospital facilities dedicated to Phase I cancer research studies, and setting itself apart as a leader in immunotherapy and vaccine therapy, surgical robotics, vitamin D research, tumor microenvironment, personalized medicine, cancer genetics and prevention.
Committing the infrastructure, intellectual capital and necessary resources to convert its scientific discoveries into products and applications, RPCI has helped establish numerous life science companies, 13 bio-tech spin-off companies, and has formed strategic partnerships with investigators and centers throughout the world. RPCI’s strong basic and clinical research programs attracted major research grants and contracts totaling more than $81 million. RPCI is nationally recognized as a cancer research pioneer, and currently sponsors more than 540 research funded projects of promising new cancer treatments.
Ranked as one of the nation’s top cancer hospitals by U.S. News & World Report, RPCI has more than 3,100 employees who work toward the common cause of advanced treatment and education to patients of all age with for all types of cancer. RPCI actively seeks to help medically underserved and high-risk populations through its robust diversity program, stop smoking hotline, cancer registries, genetics counseling program, high-risk early detection and surveillance programs. The faculty, combined with strong alliances with local and regional colleges and universities, enables the Institute to provide a comprehensive education in several fields.
The mission of Roswell Park is to understand, prevent and cure cancer.
Roswell Park Cancer Institute is led by:
- Candace S. Johnson, PhD, President & CEO
- Michael Joseph, Chairman of the Board